Determine Role of IL-5 and Eosinophils in Chronic Bronchial Asthma

Authors

  • Mustafa Hamoodi Jabbar 5University of AL- Qadisiyah, AL-Diwanyia, Iraq.
  • Nasreen Rahman Mohammed University of AL- Qadisiyah, AL-Diwanyia, Iraq.
  • Fadhaa Jaber Shinjar University of AL- Qadisiyah, AL-Diwanyia, Iraq
  • Heba Suhail kadhem University of AL- Qadisiyah, AL-Diwanyia, Iraq.
  • Zainab Abd Ali Salman University of AL- Qadisiyah, AL-Diwanyia, Iraq

Keywords:

Asthma, Eosinophils, ELISA

Abstract

Asthma is a chronic inflammatory disease, primarily resulting from interactions between genetic and environmental factors, in which immunological mediators and cells play a key role. This study aimed to determine role IL-5 and eosinophilia in chronic asthma

References

Amruta N., Kandikattu H. K. (2018). Apoptosis of inflammatory cells in asthma. Int. J. Cell Biol. Physiol. 1, 1–6.

Anderson W. C., III., Szefler S. J. (2019). Cost-effectiveness and comparative effectiveness of biologic therapy for asthma. Ann. Allergy Asthma Immunol. 122, 367–372.

Bagnasco D., Ferrando M., Varricchi G., Puggioni F., Passalacqua G., Canonica G. W., et al. (2017). Anti-interleukin 5 (IL-5) and IL-5Rα biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front. Med. 4:135.

Bel E. H., Wenzel S. E., Thompson P. J., Prazma C. M., Keene O. N., Yancey S. W., et al. (2014). Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189–1197.

Khadhim M.M., AL-Damerchi A.T., Kazaal M.A. (2015). Evaluation of A Disintegrin and Metalloprotein33 Gene Polymorphism in Bronchial Asthma. AL-Qadisiya Medical Journal. 11(19), 1-9.

Bhalla A., Mukherjee M., Nair P. (2018). Airway eosinophilopoietic and autoimmune mechanisms of eosinophilia in severe asthma. Immunol. Allergy Clin. N. Am. 38, 639–654.

Shaheed O.S., Kazaal M.A. (2017). Association of a Disintegrin and Metalloproteinase 33 Gene Polymorphisms with Chronic Obstructive Pulmonary Disease in Iraqi Population. J. Pharm. Sci. & Res. 9(10), 2240-2243.

Mukherjee M., Nair P. (2018). Autoimmune responses in severe asthma. Allergy Asthma Immunol Res. 10, 428- 447.

Broughton S. E., Dhagat U., Hercus T. R., Nero T. L., Grimbaldeston M. A., Bonder C. S., et al. (2012). The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol. Rev. 250, 277–302.

Bochner B. S., Gleich G. J. (2010). What targeting eosinophils has taught us about their role in diseases. J. Allergy Clin. Immunol. 126, 16–25.

Brusselle G., Germinaro M., Weiss S., Zangrilli J. (2017). Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm. Pharmacol. Ther. 43, 39–45

Chipps B. E., Newbold P., Hirsch I., Trudo F., Goldman M. (2018). Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann. Allergy Asthma Immunol. 120, 504–511.

Devos R., Guisez Y., Plaetinck G., Cornelis S., Tavernier J., van der Heyden J., et al. (1994). Covalent modification of the interleukin-5 receptor by isothiazolones leads to inhibition of the binding of interleukin-5. Eur. J. Biochem. 225, 635–640.

Dorman S. C., Efthimiadis A., Babirad I., Watson R. M., Denburg J. A., Hargreave F. E., et al. (2004). Sputum CD34+ IL-5Rα+ cells increase after allergen: evidence for in situ eosinophilopoiesis. Am. J. Respir. Crit. Care Med. 169, 573–577.

Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G. W., & Heffler, E. (2019). Interleukin-5 in the Pathophysiology of Severe Asthma. Frontiers in physiology, 10, 1514.

Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M. S., et al. (2003). Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112, 1029–1036.

Ghazi A., Trikha A., Calhoun W. J. (2012). Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert. Opin. Biol. Ther. 12, 113–118.

Kazaal M.A., Habeeb A.A., Hasan H.N. (2023). Evaluation Role of IL-13 and Eosinophils in Adult Asthmatic Patients. Journal of Biomedicine and Biochemistry, 2 (2), 17-24.

Mishra V. (2004). Effect of obesity on asthma among adult Indian women. Int J Obesity. 28, 1048–1058.

Choi BS. (2021). Eosinophils and childhood asthma. Clin Exp Pediatr. 64(2),60-67.

Vergara CI., Acevedo N., Jiménez S., Martínez B., Mercado D., Gusmão L., Barnes K.C., Caraballo L. (2010). A Six-SNP haplotype of ADAM33 is associated with asthma in a population of Cartagena, Colombia. Int Arch Allergy Immunol.152(1), 32-40.

Gonzalez D., Benitez M., Quirce S. (2019). Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J. Investig. Allergol. Clin. Immunol. 29, 84–93.

Greenfeder S., Umland S. P., Cuss F. M., Chapman R. W., Egan R. W. (2001). Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir. Res. 2, 71–79.

Hakonarson H., Maskeri N., Carter C., Chuang S., Grunstein M. M. (1999). Autocrine interaction between IL-5 and IL-1beta mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. J. Clin. Invest. 104, 657–667.

Haldar P. (2017). Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biol. Ther. Dent. 11, 81–95.

Hart T. K., Cook R. M., Zia-Amirhosseini P., Minthorm E., Sellers T. S., Maleeff B. E., et al. (2001). Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol. 108, 250–257.

Ip W. K., Wong C. K., Wang C. B., Tian Y. P., Lam C. W. (2005). Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor induce adhesion and chemotaxis of human eosinophils via p38 mitogen-activated protein kinase and nuclear factor kappaB. Immunopharmacol. Immunotoxicol. 27, 371–393.

Kips J. C., O’Connor B. J., Langley S. J., Woodcock A., Kerstjens H. A., Postma D. S., et al. (2003). Effects of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167, 1655–1659.

Koike M., Nakamura K., Furuya A., Iida A., Anazawa H., Takatsu K., et al. (2009). Establishment of humanized anti-interelukin-5 receptor α chain monoclonal antibodies having a potent neutralizing activity. Hum. Antibodies 18, 17–27.

Lambrecht B. N., Hammad H. (2015). The immunology of asthma. Nat. Immunol. 16, 45–56.

McGregor M. C., Krings J. G., Nair P., Castro M. (2019). Role of biologics in asthma. Am. J. Respir. Crit. Care Med. 199, 433–445.

Nair P., Wenzel S., Rabe K. F., Bourdin A., Lugogo N. L., Kuna P., et al. (2017). Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 376, 2448–2458.

Ortega H. G., Liu M. C., Pavord I. D., Brusselle G. G., FitzGerald J. M., Chetta A., et al. (2014). Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207.

Park S. W., Kim D., Chang H. S., Park S. J., Lee Y. M., Park J. S., et al. (2003). Association of interleukin-5 and eotaxin with acute exacerbation of asthma. Int. Arch. Allergy Immunol. 131, 283–290.

Pelaia G., Vatrella A., Busceti M. T., Gallelli L., Calabrese C., Terracciano R., et al. (2015). Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediat. Inflamm. 2015:879783.

Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G. W., & Heffler, E. (2019). Interleukin-5 in the Pathophysiology of Severe Asthma. Frontiers in physiology, 10, 1514.

Downloads

Published

2023-09-07

How to Cite

Mustafa Hamoodi Jabbar, Nasreen Rahman Mohammed, Fadhaa Jaber Shinjar, Heba Suhail kadhem, & Zainab Abd Ali Salman. (2023). Determine Role of IL-5 and Eosinophils in Chronic Bronchial Asthma. Czech Journal of Multidisciplinary Innovations, 21, 14–23. Retrieved from https://peerianjournal.com/index.php/czjmi/article/view/629

Issue

Vol. 21 (2023): CZJMI

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format
  2. Adapt — remix, transform, and build upon the material
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. NonCommercial — You may not use the material for commercial purposes .
  3. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits

Most read articles by the same author(s)